Growth pattern and final height in 21-hydroxylase deficiency.

Area of Science:

• Pediatric Endocrinology
• Genetics
• Growth Disorders

Background:

• 21-hydroxylase deficiency is a common cause of congenital adrenal hyperplasia.
• Children with this condition often experience growth impairment and short stature.
• Identifying factors influencing growth is critical for optimizing management.

Purpose of the Study:

• To evaluate growth patterns and final height in children with 21-hydroxylase deficiency.
• To identify specific factors that influence growth and final height outcomes.
• To provide evidence-based recommendations for managing growth in affected children.

Main Methods:

• Retrospective analysis of growth data from 47 children diagnosed with 21-hydroxylase deficiency.
• Longitudinal follow-up from early childhood (0.6 +/- 1.2 years) for an average of 8.8 +/- 3.9 years.
• Statistical analysis to correlate growth parameters (height SDS) with clinical and laboratory variables.

Main Results:

• Final height Standard Deviation Score (SDS) was significantly lower than target height SDS (-2.5 +/- 1.4 vs. -1.0 +/- 1.0).
• Age-specific height SDS was significantly influenced by laboratory monitoring frequency and disease type (salt-wasting vs. simple virilizing).
• Univariate analysis indicated that age at treatment, lab monitoring frequency, and infant glucocorticoid dose affected final height, but these were not sustained in multivariate analysis.

Conclusions:

• Children with 21-hydroxylase deficiency exhibit significantly reduced final height compared to their genetic potential.
• Regular and consistent laboratory monitoring is essential for optimizing growth management.
• A lower glucocorticoid dose during infancy may be beneficial for improving final height outcomes in these patients.